Published in Urol Clin North Am on February 01, 2010
Treatment profile and complications associated with cryotherapy for localized prostate cancer: a population-based study. Prostate Cancer Prostatic Dis (2011) 0.86
Salvage cryotherapy for radiation-recurrent prostate cancer: outcomes and complications. Curr Urol Rep (2011) 0.82
MR imaging-guided cryoablation for the treatment of benign prostatic hyperplasia. J Vasc Interv Radiol (2011) 0.77
The feasibility and safety of repeat cryosurgical ablation of localized prostate cancer. World J Surg Oncol (2015) 0.75
Use of cryoablation beyond the prostate. Insights Imaging (2016) 0.75
Rising incidence of small renal masses: a need to reassess treatment effect. J Natl Cancer Inst (2006) 6.58
Long-term survival following partial vs radical nephrectomy among older patients with early-stage kidney cancer. JAMA (2012) 4.30
Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am (2003) 3.44
National utilization trends of partial nephrectomy for renal cell carcinoma: a case of underutilization? Urology (2006) 3.34
Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res (2003) 3.25
Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol (2005) 3.15
Use of advanced treatment technologies among men at low risk of dying from prostate cancer. JAMA (2013) 3.08
Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J Urol (2004) 3.06
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int (2005) 3.06
Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol (2002) 2.91
Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas. J Urol (2008) 2.45
Positive surgical margin appears to have negligible impact on survival of renal cell carcinomas treated by nephron-sparing surgery. Eur Urol (2009) 2.41
Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer (2007) 2.38
Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm. BJU Int (2008) 2.35
Use of restaging bladder tumor resection for bladder cancer among Medicare beneficiaries. Urology (2011) 2.06
Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol (2005) 2.05
Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol (2005) 2.05
Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer (2007) 2.00
Delays in diagnosis and bladder cancer mortality. Cancer (2010) 1.92
Tumor classification by tissue microarray profiling: random forest clustering applied to renal cell carcinoma. Mod Pathol (2005) 1.89
Secondary hormonal therapy for advanced prostate cancer. J Urol (2006) 1.86
p21 is a prognostic marker for renal cell carcinoma: implications for novel therapeutic approaches. J Urol (2007) 1.81
Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology--is up-front resection indicated and, if not, is it avoidable? J Urol (2009) 1.75
Prognostic significance of venous thrombus in renal cell carcinoma. Are renal vein and inferior vena cava involvement different? J Urol (2004) 1.70
Prognostic relevance of capsular involvement and collecting system invasion in stage I and II renal cell carcinoma. BJU Int (2007) 1.69
A matched comparison of perioperative outcomes of a single laparoscopic surgeon versus a multisurgeon robot-assisted cohort for partial nephrectomy. J Urol (2012) 1.69
Specialty care and the patient-centered medical home. Med Care (2011) 1.68
Prognostic impact of tumor size on pT2 renal cell carcinoma: an international multicenter experience. J Urol (2007) 1.67
Surgeon characteristics and long-term trends in the adoption of laparoscopic radical nephrectomy. J Urol (2011) 1.64
Smoking negatively impacts renal cell carcinoma overall and cancer-specific survival. Cancer (2011) 1.64
Prognostic value of microvascular invasion in predicting the cancer specific survival and risk of metastatic disease in renal cell carcinoma: a multicenter investigation. J Urol (2011) 1.63
Identifying risk factors for potentially avoidable complications following radical cystectomy. J Urol (2005) 1.63
Impact of surgical volume on mortality and length of stay after nephrectomy. Urology (2004) 1.62
Tumor biology and prognostic factors in renal cell carcinoma. Oncologist (2011) 1.62
Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res (2007) 1.61
Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy. Cancer (2010) 1.61
Use of American Society of Anesthesiologists physical status classification to assess perioperative risk in patients undergoing radical nephrectomy for renal cell carcinoma. Urology (2004) 1.60
Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol (2005) 1.60
Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. J Urol (2003) 1.60
Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: implications as a potential biomarker. Int J Cancer (2005) 1.59
Renal cell carcinoma with retroperitoneal lymph nodes: role of lymph node dissection. J Urol (2003) 1.59
Intraoperative thrombus embolization during nephrectomy and tumor thrombectomy: critical analysis of the University of California-Los Angeles experience. J Urol (2008) 1.59
Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance. Cancer (2008) 1.58
Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway. Clin Cancer Res (2003) 1.57
The effect that mutations in the conserved capsular polysaccharide biosynthesis genes cpsA, cpsB, and cpsD have on virulence of Streptococcus pneumoniae. J Infect Dis (2004) 1.57
Understanding the role of percutaneous biopsy in the management of patients with a small renal mass. Urology (2012) 1.55
Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol (2009) 1.55
CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis. J Urol (2009) 1.54
Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer (2008) 1.53
Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J Urol (2003) 1.52
Salvage-targeted kidney cancer therapy in patients progressing on high-dose interleukin-2 immunotherapy: the UCLA experience. Cancer J (2013) 1.52
Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol (2004) 1.52
Platelet count and preoperative haemoglobin do not significantly increase the performance of established predictors of renal cell carcinoma-specific mortality. Eur Urol (2007) 1.51
Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res (2004) 1.51
Streptococcus pneumoniae capsule biosynthesis protein CpsB is a novel manganese-dependent phosphotyrosine-protein phosphatase. J Bacteriol (2002) 1.50
Understanding criteria for surveillance of patients with a small renal mass. Urology (2012) 1.48
PC-SPES: herbal formulation for prostate cancer. Urology (2002) 1.48
Use of nephrectomy at select medical centers--a case of follow the crowd? J Urol (2006) 1.47
The regionalization of radical cystectomy to specific medical centers. J Urol (2005) 1.47
Sex, age, and surgeon decision on nephron-sparing surgery are independent predictors of renal masses with benign histologic findings--a multicenter survey. Urology (2010) 1.46
Hospice use and high-intensity care in men dying of prostate cancer. Arch Intern Med (2010) 1.45
Postoperative complications and long-term survival among patients treated surgically for renal cell carcinoma. J Urol (2011) 1.44
Fuhrman grade provides higher prognostic accuracy than nucleolar grade for papillary renal cell carcinoma. J Urol (2010) 1.44
Pathological, immunohistochemical and cytogenetic features of papillary renal cell carcinoma with clear cell features. J Urol (2010) 1.43
Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer (2008) 1.43
Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol (2004) 1.42
Surveillance strategies for renal cell carcinoma patients following nephrectomy. Rev Urol (2006) 1.41
Cancer survivorship: challenges and changing paradigms. J Urol (2008) 1.36
Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin Cancer Res (2008) 1.34
Mutational analysis of the carboxy-terminal (YGX)4 repeat domain of CpsD, an autophosphorylating tyrosine kinase required for capsule biosynthesis in Streptococcus pneumoniae. J Bacteriol (2003) 1.33
Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies. Cancer (2008) 1.32
Changing concepts in the management of renal oncocytoma. Urology (2002) 1.31
The effects of adjusting for case mix on mortality and length of stay following radical cystectomy. J Urol (2006) 1.31
Collecting duct renal cell carcinoma: clinical study of a rare tumor. J Urol (2002) 1.31
Variations in quality of care for men with early-stage prostate cancer. J Clin Oncol (2008) 1.29
Aggressive treatment for bladder cancer is associated with improved overall survival among patients 80 years old or older. Urology (2004) 1.29
Accuracy of determining small renal mass management with risk stratified biopsies: confirmation by final pathology. J Urol (2012) 1.29
Volume-based referral for cancer surgery: informing the debate. J Clin Oncol (2007) 1.29
Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy. Cancer (2003) 1.29
Epithelial cell adhesion molecule (KSA) expression: pathobiology and its role as an independent predictor of survival in renal cell carcinoma. Clin Cancer Res (2004) 1.27
Mathematical model to predict individual survival for patients with renal cell carcinoma. J Clin Oncol (2002) 1.27
Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy. J Urol (2003) 1.25
Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys (2004) 1.25
Surveillance following radical or partial nephrectomy for renal cell carcinoma. Curr Urol Rep (2005) 1.25
Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy. Cancer Epidemiol Biomarkers Prev (2009) 1.23
Cystic renal cell carcinoma: biology and clinical behavior. Urol Oncol (2004) 1.22
Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma. Urology (2003) 1.21
Clinicopathological features and prognosis of synchronous bilateral renal cell carcinoma: an international multicentre experience. BJU Int (2007) 1.19
Complications and failure to rescue after laparoscopic versus open radical nephrectomy. J Urol (2011) 1.18
Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma. J Urol (2013) 1.18
Comparative effectiveness of external-beam radiation approaches for prostate cancer. Eur Urol (2012) 1.17
Whole-body skeletal imaging in mice utilizing microPET: optimization of reproducibility and applications in animal models of bone disease. Eur J Nucl Med Mol Imaging (2002) 1.17
Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin Cancer Res (2009) 1.16
Surveillance for renal cell carcinoma: why and how? When and how often? Urol Oncol (2007) 1.16
The effects of intentional cryoablation and radio frequency ablation of renal tissue involving the collecting system in a porcine model. J Urol (2005) 1.16
Prognostic factors for renal cell carcinoma with tumor thrombus extension. J Urol (2007) 1.15
Lineage relationship between LNCaP and LNCaP-derived prostate cancer cell lines. Prostate (2004) 1.14
Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. Prostate (2003) 1.13